Investigative tools for diagnosis and management.

Area of Science:

• Genomics and Proteomics
• Oncogenomics
• Molecular Biology

Background:

• Myeloma pathogenesis is increasingly understood through genomics and proteomics.
• Novel mediators and therapeutic targets have been identified.
• Advances enable molecular classification and improved disease monitoring.

Purpose of the Study:

• To review recent advances in myeloma diagnostics, prognostics, and therapeutics.
• To highlight the role of new investigative techniques in refining myeloma management.
• To discuss the impact of molecular insights on risk stratification and treatment strategies.

Main Methods:

• Utilizing serum free light chains for diagnosis, especially in specific patient groups.
• Employing MRI and PET scans for diagnosis and bone disease management.
• Applying cytogenetics and fluorescent in situ hybridization (FISH) for prognostic assessment.
• Leveraging oncogenomic studies like expression profiling, SNP-arrays, and aCGH for pathobiology and biomarker discovery.

Main Results:

• New diagnostic tools refine workup, including for oligosecretory myeloma, renal disease, and amyloidosis.
• Advanced imaging and FISH-detected chromosomal changes (e.g., t(4;14), t(14;16), del 17p) improve risk stratification.
• Novel therapies achieve high complete response rates, necessitating redefined response categories.
• Molecular markers and stringent complete responses correlate with extended overall survival.

Conclusions:

• Genomic and proteomic advancements are revolutionizing myeloma understanding and patient care.
• Improved risk stratification and molecular classification guide personalized treatment strategies.
• Attaining deep molecular remission is crucial for improving long-term survival in myeloma patients.